Fasitibant chloride T38544
品牌 | 厂商性质 | 产地 | 货期 |
---|---|---|---|
TargetMol | 生产商 | 美国 | 现货 |
性能特点
生化试剂,可用于动物细胞实验
规格 | CAS号 | 价格 | 操作 |
---|---|---|---|
25 mg | 1157852-02-2 | ¥10,600.00 | 询底价 |
Product Introduction
Bioactivity
英文名: Fasitibant chloride
描述: Fasitibant chloride (MEN16132 free base) is a powerful and specific nonpeptide antagonist of the bradykinin B2 receptor (B2R). This compound effectively reduces joint pain and mitigates joint edema in a rat model of Carrageenan-induced arthritis.
体外活性: Fasitibant chloride (MEN16132 free base; 1 μM; pre-treatment 30 min before BK) produces a consistent reduction of the FGF-2 expression (BK induced) and decrement of BK induced-FGFR-1 phosphorylation[2]. Fasitibant chloride inhibits the phosphorylation of FRSα, ERK1/2, STAT3 (BK induced; 1 μM; for 15 min), except AKT in HUVEC[2]. Cell Viability Assay[2]Cell Line: human umbilical vein endothelial cells (HUVEC) Concentration: 1 μM Incubation Time: Pre-treatment 30 min before Bradykinin (BK; 1 μM; for 24 h) Result: Produced a consistent reduction of the FGF-2 expression (BK induced) and decrement of BK induced-FGFR-1 phosphorylation (without affecting FGFR-2 activity).
体内活性: Fasitibant chloride (MEN16132 free base; 100 μg per knee; injection into the knee; 30 min before λ-carrageenan) inhibits about 40-45% on the carrageenan-induced joint pain and knee joint oedema[1]. Animal Model: Male Wistar rats weighing 250-300 g[1]Dosage: 100 μg per knee Administration: Injection into the knee; 30 min before λ-carrageenan Result: Inhibited about 40-45% on the carrageenan-induced joint pain and knee joint oedema. Reduced the neutrophil infiltration in the synovium by about 60% and the release of prostaglandins by about 30%.
存储条件: Powder: -20°C for 3 years | In solvent: -80°C for 1 year
关键字: MEN 16132 | MEN16132 | Fasitibant Chloride | MEN-16132
Fasitibant chloride T38544信息由TargetMol中国为您提供,如您想了解更多关于Fasitibant chloride T38544报价、型号、参数等信息,欢迎来电或留言咨询。
注:该产品未在中华人民共和国食品药品监督管理部门申请医疗器械注册和备案,不可用于临床诊断或治疗等相关用途